Search
Hemoximer
go.drugbank.com/drugs/DB17600InvestigationalHemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.
LB-001
go.drugbank.com/drugs/DB17685ExperimentalLB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Deuremidevir
go.drugbank.com/drugs/DB26606InvestigationalDeuremidevir is under investigation in clinical trial NCT06328400 (A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension).
PF-06291874
go.drugbank.com/drugs/DB15065InvestigationalPF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes
LX-7101
go.drugbank.com/drugs/DB16009InvestigationalLX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).
PF-06882961
go.drugbank.com/drugs/DB16043InvestigationalPF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
Dirocaftor
go.drugbank.com/drugs/DB16143InvestigationalDirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).
AIM-102
go.drugbank.com/drugs/DB16176InvestigationalAIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic
HTPEP-001
go.drugbank.com/drugs/DB18730ExperimentalHTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.[A263527]
Domvanalimab
go.drugbank.com/drugs/DB18848InvestigationalDomvanalimab is under investigation in clinical trial NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-small